�
22 June 2018 07:00 BST
�
Publication of Prospectus
Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:
Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").
�
The last drawdown under the EMTN programme was in 2016.
�
To view the full document, please paste the following URL into the address bar of your browser.
�
http://www.rns-pdf.londonstockexchange.com/rns/2100S_1-2018-6-21.pdf
�
A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:
�
http://www.morningstar.co.uk/uk/NSM
�
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
�
|
Media Relations |
� |
� |
|
Karen Birmingham |
UK/Global |
+44 203 749 5634 |
|
Rob Skelding |
UK/Global |
+44 203 749 5821 |
|
Matt Kent |
UK/Global |
+44 203 749 5906 |
|
Gonzalo Vi�a |
UK/Global |
+44 203 749 5916 |
|
Jacob Lund |
Sweden |
+46 8�553�260 20 |
|
Michele Meixell |
US |
+1 302 885 2677 |
|
� |
� |
� |
|
Investor Relations |
� |
� |
|
Thomas Kudsk Larsen |
� � |
+44 203 749 5712 |
|
Josie Afolabi |
� |
+44 203 749 5631 |
|
Craig Marks |
Finance; Fixed Income; M&A |
+44 7881 615 764 |
|
Henry Wheeler |
Oncology |
+44 203 749 5797 |
|
Mitchell Chan |
Oncology; Other |
+1 240 477 3771 |
|
Christer Gruvris |
Brilinta ; Diabetes |
+44 203 749 5711 |
|
Nick Stone |
Respiratory; Renal |
+44 203 749 5716 |
|
Jennifer Kretzmann |
Retail Investors |
+44 203 749 5824 |
|
US toll-free |
� |
+1 866 381 7277 |
|
� |
� |
� |
|
� |
� |
� |
|
� |
� |
� |
|
� |
� |
� |
�
Adrian Kemp
Company Secretary
AstraZeneca PLC